tv.qiagenbioinformatics.com

This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations that scientists aim to elucidate from spatial transcriptomics data. We will take spatially segmented differential expression data generated using spatial transcriptomics platforms and learn how to derive biological insights across multiple experimental observations. We will walk through the following during this training:

• How to upload your spatial transcriptomics data into IPA

• How to set up core analyses

• Generate a comparison analysis across spatially segmented experimental groups

• Examine canonical pathway and upstream regulator shared or differing biology across your segmented datasets

Clinical labs face significant challenges in interpreting germline variants for hereditary disease diagnostics, including the overwhelming volume of genomic data, the complexity of variant classification, the need for rapid yet accurate interpretation, and the difficulty of maintaining up-to-date, evidence-based insights amid evolving guidelines and literature.

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary human-certified AI approach to literature curation and variant classification to streamline your interpretation workflow.

Viewers will:

• Learn about the latest enhancements to QCI Interpret for hereditary diseases, including enhanced filtering capabilities, addition of new annotation sources and efficiency improvements to reduce turnaround time.

With the rising demand for personalized cancer treatments, clinical diagnostic labs are under increasing pressure to expand their capabilities, boost test throughput, shorten turnaround times, and produce detailed, oncologist-ready reports that quickly align patients with the most suitable therapies and clinical trials. 

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab accelerate clinical reporting workflows for high-throughput precision oncology NGS testing. The webinar will showcase QCI Interpret’s ability to streamline variant interpretation by dynamically computing pathogenicity and actionability for each variant based on ACMG and AMP/ASCO/CAP guidelines, covering more than 30,000 cancer types and subtypes with full transparency and supporting references. You’ll also learn how to utilize over 600,000 pre-formulated, oncologist-reviewed variant interpretation summaries to create customizable, up-to-date, oncologist-ready reports with detailed gene, variant, diagnostic, prognostic, and therapeutic information. Additionally, attendees will get an exclusive preview of the software’s new features designed to further optimize the somatic interpretation workflow. 

Viewers will:  

•  Discover how QCI Interpret’s newly added Reflex function allows you to effortlessly resubmit a pre-analyzed test for full curation, enabling you to obtain a comprehensive expert review and content for uncurated variants with ease.  

Are you new to QIAGEN Ingenuity Pathway Analysis (IPA) or interested in expanding your skill set? Join us as we learn more on large dataset analysis and knowledge base queries using QIAGEN IPA.

You’ll learn to:

• Upload multiple dataset types (e.g., RNA-seq, proteomics, metabolomics) and perform interactive core/pathway analysis in IPA

• Learn how to interpret different results, including pathways, key regulators, impact on biological functions/diseases and more

• Compare different experimental conditions (e.g., single-cell clusters, disease types) and identify similarities and contrasts

• Generate a network for hypothesis generation, even without a dataset or experimental design.

Already have an IPA license? Install IPA and start using it now:

https://qiagen.showpad.com/share/CBv30blCPKFDUYHRWtAvI

Learn more about IPA or request a free trial: https://digitalinsights.qiagen.com/ipa

QIAGEN OmicSoft Lands are high-quality curated repositories of genomics and proteomics data sourced from public, published studies (GEO, EBI, SRA) and consortia (TCGA, CPTAC, GTEx, and more). Because of our expert curation and stringent quality checks, OmicSoft users can deeply investigate across diverse oncology and normal tissue/cell datasets to discover and validate candidate drug targets and biomarkers.

In this training, attendees will use OmicSoft Studio, our graphical user interface, to access public data from The Cancer Genome Atlas (TCGA). Using this data, you will learn how to:

• View gene expression and somatic mutation frequency across different tumor types and conditions

• Identify genes whose expression correlates or anti-correlates with mutation of your target

• Prioritize your candidate biomarkers using expression data across comparisons (tumor vs. normal, MUT vs. WT, etc.)

• Establish survival consequences from changes in your candidate biomarker’s expression or mutation status

This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations at multiple levels such as transcriptome, proteome, and metabolome. Through a series of brief technical vignettes, it is demonstrated how to:

· Generate associations among molecular signatures obtained via integrating multi-omics data

· Extract mechanisms from multi-omics data for precision medicine

· Disease stratification based on multi-omics profiles

· Map disease networks among targets and indications

Does your lab need a faster and easier way to uncover associations between gene variants, diseases, and biological pathways? As next-generation sequencing (NGS) data grows exponentially, discovering new genes implicated in hereditary diseases or cancer progression has never been more challenging or time-intensive. However, advanced bioinformatics tools and expert-curated content from QIAGEN can simplify, enrich, and accelerate your research.

Join us for an informative webinar that will provide a deep-dive into three cutting-edge solutions: QIAGEN CLC Genomics Workbench, QCI Interpret Translational, and QIAGEN Ingenuity Pathway Analysis (IPA). Attendees will learn through demonstrations how these three solutions can analyze sequencing data from a variety of NGS technologies, annotate genes using the world’s most comprehensive and up-to-date curated scientific evidence, and find biological connections in gene variants. Helping you streamline your NGS workflows from FASTQ to discovery, these three easy-to-use solutions will enable you to pinpoint disease-associated variants, uncover biological mechanisms, and turn data into breakthroughs faster than ever.

In this webinar, you’ll learn how to:

• Use the LightSpeed module of QIAGEN CLC Genomics Workbench for ultra-fast, FASTQ-to-VCF NGS data processing that can deliver whole genome or exome results in minutes.

• Leverage QCI Interpret Translational to accelerate your understanding of hereditary and tumor variants with powerful cohort analysis capabilities.

• Use QIAGEN IPA to uncover novel biological mechanisms with the world’s most comprehensive manually curated database.

This is your opportunity to speed up discoveries, gain deeper insights, and make impactful connections. Don’t miss out—your next breakthrough starts here.

Next-generation sequencing (NGS): the technology that took the biological research world by storm. Gone are the days when sequencing a whole human genome would take almost 13 years, now reduced to a day. But an abundance of data means nothing without high-quality resources – only when used together can they produce an interpretation that is accurate, timely and usable for patient care.

In our live, interactive training session on February 26, discover how you can use Human Gene Mutation Database (HGMD) Professional to streamline your lab’s variant interpretation. Explore the wealth of comprehensive, expert-curated data on inherited disease-associated germline variants and ensure that you are equipped to get the most out of NGS data.

Learn to use HGMD Pro to:

• Distinguish clinically significant variants from VUS

• Use batch search vs. advanced search

• Curate genes using HGMD Pro’s accurate, up-to-date information

• Identify the predominant genetic variant in a specific gene to understand the genetic mechanisms underlying associated diseases

• Answer other variant-related questions

Single-cell RNA-sequencing (scRNA-seq) is widely used to investigate tissue heterogeneity, identify novel cell types, study pathogenic mechanisms, develop targeted therapy (including immunotherapy) and more. Accordingly, a tremendous amount of scRNA-seq data has been deposited to public domains like GEO.

In this training, you will learn how to

· Locate public single-cell studies of interest using QIAGEN Omicsoft Single Cell Lands

· Study different cell types by dimension reduction plots (for example, t-SNE, UMAP)

· Investigate expression of genes of interest across different cell types (Violin plots, overlay expression on cluster)

· Identify key pathways and regulators from scRNA-seq data using QIAGEN Ingenuity Pathway Analysis (IPA)